Pliant Therapeutics, Inc.: Focused on developing novel therapies for treatment of fibrosis. Pliant has developed a portfolio of fully-owned development candidates focused on inhibiting the TGFb pathway through integrin inhibition. The company’s lead product candidate, PLN-74809 is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is being developed in idiopathic pulmonary fibrosis (IPF), and primary sclerosing cholangitis (PSC). Positive results of a Phase 1b clinical study of PLN-7480 showed to inhibit TGF-β activation by up to 70% in alveolar macrophages collected from healthy volunteers, in a dose- and exposure-dependent manner. The second program, PLN-1474, targets advanced/end-stage liver fibrosis, and is in IND enabling studies.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Pre-Clinical Stage
Disease Space
Rare Disease, Respiratory
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Small Molecule
Website:
Address:
260 Littlefield Avenue
South San Francisco, CA 94080
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020